Loading...
Loading...
SPPI| Name | Value |
|---|---|
| Revenues | 15.6M |
| Cost of Revenue | 1.1M |
| Gross Profit | 14.6M |
| Operating Expense | 19.4M |
| Operating I/L | -4.9M |
| Other Income/Expense | -0.1M |
| Interest Income | 0.6M |
| Pretax | -5.0M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -5.1M |
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of oncology and hematology drug products. Their pipeline includes Eflapegrastim, a long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, an irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule in Phase I development for relapsed or refractory non-Hodgkin's lymphoma. The company generates revenue through co-development, commercialization, and in-license agreements with pharmaceutical companies and research institutions, allowing them to bring innovative treatments to market and address unmet medical needs.
